Neurocrine biosciences reports fourth quarter and fiscal 2021 financial results and provides financial expectations for fiscal 2022

San diego, feb. 11, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the fourth quarter and fiscal year ended december 31, 2021 and provided financial guidance for 2022. "as we exited last year with restored growth for ingrezza, investments we are making this year will further accelerate our ability to help many more patients with tardive dyskinesia who remain undiagnosed and untreated.
NBIX Ratings Summary
NBIX Quant Ranking